| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/26/2023 | 209.45% | Goldman Sachs | $82.47 → $73.34 | Maintains | Buy |
| 10/17/2023 | 170.04% | JP Morgan | $67 → $64 | Maintains | Overweight |
| 10/09/2023 | 195.36% | Cantor Fitzgerald | → $70 | Reiterates | Overweight → Overweight |
| 09/18/2023 | 195.36% | Cantor Fitzgerald | → $70 | Reiterates | Overweight → Overweight |
| 08/10/2023 | 195.36% | Cantor Fitzgerald | → $70 | Initiates Coverage On | → Overweight |
| 06/12/2023 | 163.71% | B of A Securities | $75 → $62.5 | Maintains | Buy |
| 05/11/2023 | 448.52% | Citigroup | $138 → $130 | Maintains | Buy |
| 03/16/2023 | 195.36% | JP Morgan | $79 → $70 | Maintains | Overweight |
| 11/18/2022 | 233.33% | JP Morgan | $96 → $79 | Maintains | Overweight |
| 11/11/2022 | 435.86% | Citigroup | $199 → $127 | Maintains | Buy |
| 08/09/2022 | 739.66% | Citigroup | $193 → $199 | Maintains | Buy |
| 05/12/2022 | 714.35% | Citigroup | $198 → $193 | Maintains | Buy |
| 05/11/2022 | 300.84% | SVB Leerink | $101 → $95 | Maintains | Outperform |
| 04/21/2022 | 326.16% | SVB Leerink | $102 → $101 | Maintains | Outperform |
| 04/04/2022 | 372.57% | JP Morgan | $136 → $112 | Maintains | Overweight |
| 03/02/2022 | 330.38% | SVB Leerink | $194 → $102 | Maintains | Outperform |
| 12/15/2021 | 473.84% | JP Morgan | $189 → $136 | Maintains | Overweight |
| 11/11/2021 | 815.61% | Citigroup | $222 → $217 | Maintains | Buy |
| 11/10/2021 | 718.57% | SVB Leerink | $200 → $194 | Maintains | Outperform |
| 10/12/2021 | — | Bernstein | Initiates Coverage On | → Market Perform | |
| 06/01/2021 | 752.32% | SVB Leerink | $192 → $202 | Maintains | Outperform |
| 04/14/2021 | 710.13% | SVB Leerink | $183 → $192 | Maintains | Outperform |
| 02/03/2021 | 697.47% | SVB Leerink | $107 → $189 | Maintains | Outperform |
| 09/10/2020 | 300.84% | SVB Leerink | $93 → $95 | Maintains | Outperform |
| 12/30/2019 | 254.43% | Citigroup | $65 → $84 | Maintains | Buy |
| 09/04/2019 | — | China Renaissance | Initiates Coverage On | → Buy | |
| 07/05/2019 | — | Macquarie | Initiates Coverage On | → Outperform | |
| 01/29/2019 | 46.41% | Credit Suisse | → $34.7 | Initiates Coverage On | → Outperform |
What is the target price for Zai Lab (ZLAB)?
The latest price target for Zai Lab (NASDAQ: ZLAB) was reported by Goldman Sachs on October 26, 2023. The analyst firm set a price target for $73.34 expecting ZLAB to rise to within 12 months (a possible 209.45% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zai Lab (ZLAB)?
The latest analyst rating for Zai Lab (NASDAQ: ZLAB) was provided by Goldman Sachs, and Zai Lab maintained their buy rating.
When is the next analyst rating going to be posted or updated for Zai Lab (ZLAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zai Lab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zai Lab was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
Is the Analyst Rating Zai Lab (ZLAB) correct?
While ratings are subjective and will change, the latest Zai Lab (ZLAB) rating was a maintained with a price target of $82.47 to $73.34. The current price Zai Lab (ZLAB) is trading at is $23.70, which is out of the analyst's predicted range.